← Back to Search

MRI Scanning for Pancreatic Cancer Detection (DWI-PDAC Trial)

Q: What is the magnitude of individuals enrolled in this clinical experiment?

<p>Affirmative. The information on clinicaltrials.gov shows that this experiment is currently enlisting individuals, which was first uploaded on March 28th 2022. There are 40 people required for the study in a single medical centre and it has been recently updated as of April 20th 2022.</p>

Q: Are there any opportunities for enrolment in this trial currently?

<p>According to clinicaltrials.gov, sign-ups are still being accepted for this medical trial. It was initially posted on March 28th 2022 and an update was applied April 20th of the same year.</p>

N/A

Recruiting

Led By Alexandre Brind'Amour, MD

Research Sponsored by Laval University

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

CA 19-9 ≥ 400 U/mL with normal bilirubin level (< 40)

Tumor size ≥ 3 cm

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 30 months

Awards & highlights

DWI-PDAC Trial Summary

This trial is looking at whether adding a MRI scan to the usual CT scan helps doctors better understand if a person with pancreatic cancer also has cancer in the lining of their abdomen.

Who is the study for?

This trial is for individuals with confirmed pancreatic ductal adenocarcinoma that can potentially be removed by surgery. They should have a tumor size of at least 3 cm and elevated CA 19-9 levels without distant metastases. Participants must be physically fit enough for pancreatic resection (ECOG performance status of 0 or 1).Check my eligibility

What is being tested?

The study is testing the effectiveness of whole-body diffusion-weighted MRI in detecting peritoneal metastases in patients with high-risk pancreatic cancer, comparing its results to those from CT scans and correlating them with findings during surgery.See study design

What are the potential side effects?

As this trial involves diagnostic imaging, there are minimal side effects associated with MRI; however, some may experience discomfort or anxiety in the scanner. There's also a small risk of an allergic reaction to any contrast material if used.

DWI-PDAC Trial Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

My CA 19-9 levels are high, but my bilirubin is normal.

Select...

My tumor is larger than 3 cm.

Select...

My cancer has not spread to distant parts of my body.

Select...

I am fit for surgery to remove part of my pancreas.

Select...

My disease can potentially be removed with surgery, as shown by a CT scan.

Select...

I have been diagnosed with pancreatic cancer.

DWI-PDAC Trial Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 30 months

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~30 months

This trial's timeline: 3 weeks for screening, Varies for treatment, and 30 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Peritoneal findings

Unexpected abortion

Secondary outcome measures

Early distant recurrence

DWI-PDAC Trial Design

1Treatment groups

Experimental Treatment

Group I: DWI-MRIExperimental Treatment1 Intervention

Patients to undergo DWI-MRI (patients include in the study.

0 / 6Eligibility criteria met

Find a Location

Who is running the clinical trial?

Laval UniversityLead Sponsor

417 Previous Clinical Trials

172,232 Total Patients Enrolled

Alexandre Brind'Amour, MDPrincipal InvestigatorLaval University

2 Previous Clinical Trials

41 Total Patients Enrolled

Media Library

Whole-body diffusion-weighted magnetic resonance imaging Clinical Trial Eligibility Overview. Trial Name: NCT05340569 — N/A

Pancreatic Adenocarcinoma Research Study Groups: DWI-MRI

Pancreatic Adenocarcinoma Clinical Trial 2023: Whole-body diffusion-weighted magnetic resonance imaging Highlights & Side Effects. Trial Name: NCT05340569 — N/A

Whole-body diffusion-weighted magnetic resonance imaging 2023 Treatment Timeline for Medical Study. Trial Name: NCT05340569 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is the magnitude of individuals enrolled in this clinical experiment?

"Affirmative. The information on clinicaltrials.gov shows that this experiment is currently enlisting individuals, which was first uploaded on March 28th 2022. There are 40 people required for the study in a single medical centre and it has been recently updated as of April 20th 2022."

Answered by AI

Are there any opportunities for enrolment in this trial currently?

"According to clinicaltrials.gov, sign-ups are still being accepted for this medical trial. It was initially posted on March 28th 2022 and an update was applied April 20th of the same year."

Answered by AI